TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Function Oncology's New Partnership with Volastra Therapeutics Marks a Milestone in Precision Medicine

Tuesday, March 26, 2024

Function Oncology and Volastra Therapeutics have announced a new collaboration in research and development. Function Oncology specializes in using CRISPR-powered platform technology to transform precision medicine. Volastra Therapeutics focuses on innovative cancer treatments targeting chromosomal instability (CIN). Together, they aim to broaden the use of Volastra’s KIF18A inhibitors across various solid tumor indications.

Function Oncology’s CRISPR-enabled platform allows for detailed understanding of diseases at a patient-specific level, moving beyond traditional gene sequencing to measure gene function. This collaboration aims to identify patients who would benefit from Volastra’s KIF18A inhibitors. The technology has the potential to speed up clinical development through predictive biomarkers and novel target validation, leading to improved patient outcomes.

Dr. Srinath Sampath, Co-founder and CEO of Function Oncology, commented on the collaboration, expressing excitement about advancing promising therapies for patients and their families. Dr. Scott Drutman, Chief Medical Officer and Head of R&D at Volastra, also expressed enthusiasm for the collaboration and the potential of Function’s innovative platform to expand patient access to KIF18A inhibitors.


patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit